Rat CTX-1 ELISA Kit (Colorimetric)

ELISA: Rat CTX-1 ELISA Kit (Colorimetric) [NBP2-69077] - Samples were spiked with high concentrations of Rat CTX-1 and diluted with Reference Standard & Sample Diluent to produce samples with values within the range of the assay.

ELISA: Rat CTX-1 ELISA Kit (Colorimetric) [NBP2-69077] - Standard Curve Reference

• Reactivity: Rt
• Applications: ELISA
• Suitable Sample Type: Serum, plasma and other biological fluids
• Standard Curve Range: 0.16 - 10 ng/mL
• Sensitivity: 0.10 ng/mL

Rat CTX-1 ELISA Kit (Colorimetric) Summary

• Specificity: This kit recognizes Rat CTX1 in samples. No significant cross-reactivity or interference between Rat CTX1 and analogues was observed.
• Standard Curve Range: 0.16 - 10 ng/mL
• Sensitivity: 0.10 ng/mL
• Assay Type: Sandwich-ELISA
• Inter-Assay: CV% < 5%
• Intra-Assay: CV% < 4.87%
• Spike Recovery: 92-110%
• Sample Volume: 100 uL
• Kit Type: ELISA Kit (Colorimetric)

Applications/Dilutions

• Dilutions:
  • ELISA

Packaging, Storage & Formulations

• Storage: Storage of components varies. See protocol for specific instructions.

Alternate Names for Rat CTX-1 ELISA Kit (Colorimetric)

• Collagen Type 1 C-Telopeptide
• Cross Linked C-telopeptide of Type I Collagen
• CTX
• CTXI

Background

CTX-1, also referred to as either carboxy-terminal cross-linked telopeptide of type 1 collagen or C-terminal end of the telopeptide of type I collagen, is a marker of osteoporosis and bone resorption (1,2). CTX-1 is a common bone turnover marker (BTM) that can easily be measured in the plasma, serum, or urine (1-3). Bone turnover refers to the removal of old bones by resorption followed by generation of new bones (3). CTX-1 is released from intact collagen type 1 by cathepsin K cleavage and can be detected by an antibody against the eight amino acid sequence EKAHDGGR (2,4). Levels of CTX-1 show circadian rhythm variabilities altered by food intake, which makes timing of sample collection an important consideration and is typically done in a fasted state (1,3). Studies show that increased levels of CTX-1 along with bone-specific alkaline phosphatase (BSALP) is associated with increased risk for bone fractures and osteoporosis (3). The most common treatment for osteoporosis is bisphosphonates, which are classified as anti-resorptive drugs that slow the removal of bone (1,3). Another treatment is the Denosumab, a monoclonal antibody for receptor activator of NFkappaB ligand, which shows decreased levels of CTX-1 and other markers within the first 24-hours of treatment (1-3). Conversely, anabolic therapies add bone by focusing on the osteoclast and osteoblast populations. Romosozumab is one specific anabolic drug that showed quick decrease in CTX-1 levels following treatment (2,3).

References

1. Williams, C., & Sapra, A. (2020). Osteoporosis Markers. In StatPearls. StatPearls Publishing.

2. Szulc P. (2018). Bone turnover: Biology and assessment tools. Best Practice & Research. Clinical Endocrinology & Metabolism. https://doi.org/10.1016/j.beem.2018.05.003

3. Park, S. Y., Ahn, S. H., Yoo, J. I., Chung, Y. J., Jeon, Y. K., Yoon, B. H., Kim, H. Y., Lee, S. H., Lee, J., & Hong, S. (2019). Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment. Journal of Bone Metabolism. https://doi.org/10.11005/jbm.2019.26.4.213

4. Cremers, C., Garnero, P., Seibel, M. J. (2008). Chapter 87- Biochemical Markers of Bone Metabolism. Principles of Bone Biology (Third Edition). https://doi.org/10.1016/B978-0-12-373884-4.00020-3.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. ELISA Kits are guaranteed for 6 months from date of receipt.

Publications for CTX-1 ELISA Kit (NBP2-69077)(4)

Publications using NBP2-69077

• Fei Wei, Megan Hughes, Mahmoud Omer, Christopher Ngo, Abinaya Sindu Pugazhendhi, Elayaraja Kolanthai, Matthew Aceto, Yasmine Ghattas, Mehdi Razavi, Thomas J Kean, Sudipta Seal, Melanie Coathup A Multifunctional Therapeutic Strategy Using P7C3 as A Countermeasure Against Bone Loss and Fragility in An Ovariectomized Rat Model of Postmenopausal Osteoporosis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2024-03-13 [PMID: 38477537]
• F Wei, CJ Neal, TS Sakthivel, Y Fu, M Omer, A Adhikary, S Ward, KM Ta, S Moxon, M Molinari, J Asiatico, M Kinzel, SN Yarmolenko, V San Cheong, N Orlovskaya, R Ghosh, S Seal, M Coathup A novel approach for the prevention of ionizing radiation-induced bone loss using a designer multifunctional cerium oxide nanozyme Bioactive materials, 2022-09-21;21(0):547-565. 2022-09-21 [PMID: 36185749] (ELISA, Human)
• Jiang A, Gao S, Zhao Z et al. Phenotype changes of subchondral plate osteoblasts based on a rat model of ovariectomy-induced osteoarthritis Ann Transl Med 2020-04-01 [PMID: 32395520] (ELISA, Rat)
• Zhang Q, Tang X, Liu Z et al. Hesperetin Prevents Bone Resorption by Inhibiting RANKL-Induced Osteoclastogenesis and Jnk Mediated Irf-3/c-Jun Activation. Front Pharmacol 2018-09-11 [PMID: 30254586] (ELISA, Human)